UY37103A - Compuestos de piperidina sustituido y su uso - Google Patents
Compuestos de piperidina sustituido y su usoInfo
- Publication number
- UY37103A UY37103A UY0001037103A UY37103A UY37103A UY 37103 A UY37103 A UY 37103A UY 0001037103 A UY0001037103 A UY 0001037103A UY 37103 A UY37103 A UY 37103A UY 37103 A UY37103 A UY 37103A
- Authority
- UY
- Uruguay
- Prior art keywords
- substituted compounds
- piperidine substituted
- agonist activity
- orexin receptor
- type
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- -1 piperidine compound Chemical class 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporciona un compuesto sustituido de piperidina que tiene una actividad agonista del receptor de orexina de tipo 2. Un compuesto representado por la fórmula (I): en donde cada símbolo es como se describe en la descripción o una de sus sales tiene una actividad agonista del receptor de orexina de tipo 2 y es de utilidad como un agente preventivo o terapéutico para narcolepsia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016019834 | 2016-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37103A true UY37103A (es) | 2017-08-31 |
Family
ID=58054473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037103A UY37103A (es) | 2016-02-04 | 2017-02-02 | Compuestos de piperidina sustituido y su uso |
Country Status (35)
Country | Link |
---|---|
US (5) | US10287305B2 (es) |
EP (2) | EP3984994A1 (es) |
JP (1) | JP6609060B2 (es) |
KR (1) | KR20180103985A (es) |
CN (2) | CN114181136A (es) |
AR (1) | AR107519A1 (es) |
AU (1) | AU2017215021B2 (es) |
BR (1) | BR112018015574B1 (es) |
CA (1) | CA3013428C (es) |
CL (1) | CL2018002099A1 (es) |
CO (1) | CO2018008705A2 (es) |
CY (1) | CY1125003T1 (es) |
DK (1) | DK3411358T3 (es) |
EA (1) | EA036166B1 (es) |
EC (1) | ECSP18066504A (es) |
ES (1) | ES2907373T3 (es) |
HR (1) | HRP20220127T1 (es) |
HU (1) | HUE057696T2 (es) |
IL (1) | IL260835B (es) |
LT (1) | LT3411358T (es) |
MA (1) | MA43963A (es) |
MX (1) | MX2018009494A (es) |
MY (1) | MY186905A (es) |
PH (1) | PH12018501666A1 (es) |
PL (1) | PL3411358T3 (es) |
PT (1) | PT3411358T (es) |
RS (1) | RS62861B1 (es) |
SG (1) | SG11201806429PA (es) |
SI (1) | SI3411358T1 (es) |
TN (1) | TN2018000262A1 (es) |
TW (2) | TW202220959A (es) |
UA (1) | UA122433C2 (es) |
UY (1) | UY37103A (es) |
WO (1) | WO2017135306A1 (es) |
ZA (1) | ZA201805544B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3411358T (lt) * | 2016-02-04 | 2022-04-25 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys ir jo naudojimas |
AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
IL300063B2 (en) | 2017-08-03 | 2024-02-01 | Takeda Pharmaceuticals Co | Methanesulfonamide and its use for the prevention or treatment of narcolepsy |
US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
US11673867B2 (en) | 2017-12-12 | 2023-06-13 | University Of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt |
EA039459B1 (ru) * | 2017-12-25 | 2022-01-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа |
WO2020004537A1 (ja) * | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JP7339250B2 (ja) * | 2018-06-29 | 2023-09-05 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
AU2020215380A1 (en) | 2019-01-31 | 2021-08-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
EP4028003A1 (en) * | 2019-09-13 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |
JP2022547711A (ja) * | 2019-09-13 | 2022-11-15 | 武田薬品工業株式会社 | ナルコレプシーの治療に使用するためのtak-925 |
BR112022009938A2 (pt) * | 2019-11-25 | 2022-09-13 | Alkermes Inc | Compostos macrocíclicos substituídos e métodos de tratamento relacionados |
CN115003655A (zh) * | 2019-11-27 | 2022-09-02 | 住友制药株式会社 | 环烷基脲衍生物 |
US20230037557A1 (en) * | 2019-11-27 | 2023-02-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
KR20220127245A (ko) | 2020-01-10 | 2022-09-19 | 다케다 야쿠힌 고교 가부시키가이샤 | 사이토크롬 p450의 억제제를 사용하여 메틸 3-((메틸술포닐)아미노)-2-(((4-페닐시클로헥실)옥시)메틸)피페리딘-1-카르복실레이트 또는 그의 염의 약동학을 향상시키거나 혈장 농도를 증가시키기 위한 방법 |
EP4200295A1 (en) | 2020-08-18 | 2023-06-28 | Merck Sharp & Dohme LLC | Bicycloheptane pyrrolidine orexin receptor agonists |
EP4247801A1 (en) * | 2020-11-23 | 2023-09-27 | Merck Sharp & Dohme LLC | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
US20220194958A1 (en) | 2020-12-21 | 2022-06-23 | Alkermes, Inc. | Substituted Macrocyclic Compounds and Related Methods of Treatment |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
AR125073A1 (es) | 2021-03-12 | 2023-06-07 | Takeda Pharmaceuticals Co | Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina |
EP4313045A1 (en) | 2021-04-02 | 2024-02-07 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for post operation recovery |
WO2022232025A1 (en) | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
AU2022269811A1 (en) * | 2021-05-03 | 2023-11-16 | Jazz Pharmaceuticals Ireland Limited | Orexin receptor agonists and uses thereof |
CN117651703A (zh) | 2021-05-26 | 2024-03-05 | 阿尔克姆斯有限公司 | 取代的氨基甲酸大环化合物及其相关治疗方法 |
EP4347046A1 (en) | 2021-05-26 | 2024-04-10 | Alkermes, Inc. | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
CN117561238A (zh) | 2021-05-26 | 2024-02-13 | 住友制药株式会社 | 苯基脲衍生物 |
WO2023199091A1 (en) | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2023204291A1 (ja) * | 2022-04-22 | 2023-10-26 | 住友ファーマ株式会社 | ビシクロアミンカルボキサミド誘導体 |
WO2023249871A1 (en) * | 2022-06-21 | 2023-12-28 | Alkermes, Inc. | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment |
WO2023249872A1 (en) * | 2022-06-21 | 2023-12-28 | Alkermes, Inc. | Substituted fused bicyclic compounds and related methods of treatment |
WO2024095158A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
US11987586B1 (en) | 2022-10-31 | 2024-05-21 | Takeda Pharmaceutical Company Limited | Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608602A1 (fr) | 1986-12-23 | 1988-06-24 | Cerm Cent Europ Rech Mauvernay | Nouvelles 3-piperidineamines ou 3-azepineamines substituees, leur preparation et leurs applications en therapeutique |
SE9003652D0 (sv) | 1990-11-15 | 1990-11-15 | Astra Ab | New heterocyclic compounds |
JPH11514333A (ja) | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
KR20000064601A (ko) | 1996-03-15 | 2000-11-06 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 신규의n-7-헤테로시클릴피롤로[2,3-d]피리딘및�그의용도 |
PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
US6750344B1 (en) | 1997-09-05 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Amine compounds and combinatorial libraries comprising same |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
AU6615300A (en) | 1999-07-30 | 2001-02-19 | Board Of Trustees Of The Leland Stanford Junior University | Hypocretin and hypocretin receptors in regulation of sleep and related disorders |
WO2001074162A1 (en) | 2000-04-04 | 2001-10-11 | The Regents Of The University Of California | Treatment of sleep disorders with hypocretin-1 |
EP1581648A2 (en) | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
DE60320302T2 (de) | 2002-12-13 | 2009-05-20 | Janssen Pharmaceutica N.V. | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors |
US20110053859A1 (en) | 2007-10-10 | 2011-03-03 | The U. S. Government Respresented by the Department of Veterans Affairs | Methods to reduce the effects of sleep deprivation |
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
AU2011232657A1 (en) | 2010-03-26 | 2012-09-27 | Merck Sharp & Dohme Corp. | Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use |
JP5976011B2 (ja) * | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
JP2014520876A (ja) | 2011-07-20 | 2014-08-25 | ウニヴェルシテ ピエール エ マリー キュリー(パリ 6) | イミノ糖c−グリコシド、その製造および使用 |
WO2014006402A1 (en) * | 2012-07-03 | 2014-01-09 | Heptares Therapeutics Limited | Orexin receptor antagonists |
WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
WO2015048091A1 (en) | 2013-09-24 | 2015-04-02 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
BR112016013299A2 (pt) | 2013-12-12 | 2017-08-08 | Univ Tsukuba | Composto |
CA2941663C (en) | 2014-03-06 | 2020-02-18 | Shanghai Haiyan Pharmaceutical Technology Co. Ltd | Piperidine derivatives as orexin receptor antagonist |
WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
JP6746107B2 (ja) | 2015-02-19 | 2020-08-26 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
JP6189905B2 (ja) | 2015-09-30 | 2017-08-30 | 株式会社スクウェア・エニックス | ビデオゲーム処理プログラム、及びビデオゲーム処理システム |
LT3411358T (lt) * | 2016-02-04 | 2022-04-25 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys ir jo naudojimas |
-
2017
- 2017-02-01 LT LTEPPCT/JP2017/003610T patent/LT3411358T/lt unknown
- 2017-02-01 SI SI201731054T patent/SI3411358T1/sl unknown
- 2017-02-01 UA UAA201809035A patent/UA122433C2/uk unknown
- 2017-02-01 MY MYPI2018702715A patent/MY186905A/en unknown
- 2017-02-01 CA CA3013428A patent/CA3013428C/en active Active
- 2017-02-01 BR BR112018015574-8A patent/BR112018015574B1/pt active IP Right Grant
- 2017-02-01 EP EP21209107.8A patent/EP3984994A1/en active Pending
- 2017-02-01 MA MA043963A patent/MA43963A/fr unknown
- 2017-02-01 PL PL17705706T patent/PL3411358T3/pl unknown
- 2017-02-01 TN TNP/2018/000262A patent/TN2018000262A1/en unknown
- 2017-02-01 HR HRP20220127TT patent/HRP20220127T1/hr unknown
- 2017-02-01 DK DK17705706.4T patent/DK3411358T3/da active
- 2017-02-01 EA EA201891742A patent/EA036166B1/ru not_active IP Right Cessation
- 2017-02-01 JP JP2018540491A patent/JP6609060B2/ja active Active
- 2017-02-01 KR KR1020187023351A patent/KR20180103985A/ko not_active Application Discontinuation
- 2017-02-01 US US15/421,702 patent/US10287305B2/en active Active
- 2017-02-01 CN CN202111369338.0A patent/CN114181136A/zh active Pending
- 2017-02-01 RS RS20220092A patent/RS62861B1/sr unknown
- 2017-02-01 WO PCT/JP2017/003610 patent/WO2017135306A1/en active Application Filing
- 2017-02-01 HU HUE17705706A patent/HUE057696T2/hu unknown
- 2017-02-01 CN CN201780021073.0A patent/CN108884043B/zh active Active
- 2017-02-01 PT PT177057064T patent/PT3411358T/pt unknown
- 2017-02-01 SG SG11201806429PA patent/SG11201806429PA/en unknown
- 2017-02-01 MX MX2018009494A patent/MX2018009494A/es unknown
- 2017-02-01 EP EP17705706.4A patent/EP3411358B1/en active Active
- 2017-02-01 US US16/075,240 patent/US10508083B2/en active Active
- 2017-02-01 AU AU2017215021A patent/AU2017215021B2/en active Active
- 2017-02-01 ES ES17705706T patent/ES2907373T3/es active Active
- 2017-02-02 UY UY0001037103A patent/UY37103A/es not_active Application Discontinuation
- 2017-02-02 TW TW111101305A patent/TW202220959A/zh unknown
- 2017-02-02 TW TW106103448A patent/TWI755374B/zh active
- 2017-02-02 AR ARP170100262A patent/AR107519A1/es unknown
-
2018
- 2018-07-29 IL IL260835A patent/IL260835B/en unknown
- 2018-08-03 CL CL2018002099A patent/CL2018002099A1/es unknown
- 2018-08-03 PH PH12018501666A patent/PH12018501666A1/en unknown
- 2018-08-20 ZA ZA201805544A patent/ZA201805544B/en unknown
- 2018-08-21 CO CONC2018/0008705A patent/CO2018008705A2/es unknown
- 2018-09-04 EC ECSENADI201866504A patent/ECSP18066504A/es unknown
-
2019
- 2019-05-13 US US16/410,463 patent/US10898737B2/en active Active
- 2019-12-13 US US16/713,667 patent/US11292766B2/en active Active
-
2021
- 2021-01-21 US US17/154,712 patent/US20220081399A1/en not_active Abandoned
-
2022
- 2022-02-22 CY CY20221100147T patent/CY1125003T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018008705A2 (es) | Compuestos de piperidina sustituido y su uso | |
CL2020000272A1 (es) | Compuesto heterocíclico y su uso. | |
CO2021011188A2 (es) | Compuesto heterocíclico y su uso | |
CL2018001181A1 (es) | Inhibidores de ret | |
CL2017000541A1 (es) | Compuestos y composiciones como inhibidores de raf kinasa | |
GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
CL2016000400A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. | |
CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
UY34832A (es) | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
CR20140218A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas iii | |
CO6491037A2 (es) | Derivados de pirazinooxazepina | |
CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
UY35151A (es) | Compuestos de 2-[fenoxi-fenil]-1-[1,2,4]triazol-1-il-etanol sustituido y su uso como fungicidas | |
AR097665A1 (es) | Trifluorometilpirimidinonas disustituidas y su uso | |
CR20180089A (es) | Compuestos útiles para inhibir a ror-gamma-t | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
CL2017000663A1 (es) | Uso de compuestos heterocíclicos fluoroalquenil sulfano para repeler moluscos | |
AR102053A1 (es) | Eliminación de dióxido de carbono de una corriente de fluido | |
CO2019012270A2 (es) | Compuesto heterocíclico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230601 |